Anavex Life Sciences Corp (AVXL)

[frrol]

That wouldn't make sense, for many reasons. I can go into it if you want me to, but it should be easy to see.

Instead, consider a couple things. The company did a dose dependency reporting really early on (5 weeks including a washout!) so it was extremely preliminary and clearly weak. They never did an update of that.

They did a sub group reporting at 31 weeks. They never did an update of that either, or even mentioned the two specific sub groups again.

Now combine these two with the hiring of Ariana. And then consider the announcement of doing genome sequencing. That's digging deep.

It shows that the company dealing with puzzling response data, and trying to get help with it, and digging deep. Dose dependency is the first, easiest, and most important potential correlative, and the first one researchers and the FDA look at. And it is apparently not where it should be at 18 months - it's still weak.

Biotech is for the patient. It is difficult to develop therapies, test then, and prove them, and it is always risky. It's why biotech stocks are so volatile. We are not unique in this regard.

Looking forward to the next update. I'm holding onto my shares.